Blockade of IL-6 signaling with anti-IL-6 antibodies suppresses experimented autoimmune MG (EAMG), indicating IL-6 may be a potential target for modulation of autoimmune responses in MG[20]. Here, IL6 is linked to myasthenia gravis.